StockData
Geron Corp logo

Geron Corp (GERN) stock

GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$1.00+0.06 (+6.17%)

Close on Nov 17, 2026Market cap $642.47MP/E –Yield –

Geron ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Geron's ebitda for the twelve months ending Jun 30, 2026 was -$51.28M. For fiscal 2025 it was -$68.11M. The highest annual figure on record is -$68.11M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$68.11M–
FY2024Dec 31, 2024-$173.19M–
FY2023Dec 31, 2023-$193.50M–
FY2022Dec 31, 2022-$138.26M–
FY2021Dec 31, 2021-$113.78M–
FY2020Dec 31, 2020-$76.76M–
FY2019Dec 31, 2019-$72.44M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.36M–
Q1 FY2026Mar 31, 2026$292.00K–
Q4 FY2025Dec 31, 2025-$25.45M–
Q3 FY2025Sep 30, 2025-$13.76M–
Q2 FY2025Jun 30, 2025-$12.33M–
Q1 FY2025Mar 31, 2025-$16.57M–
Q4 FY2024Dec 31, 2024-$19.91M–
Q3 FY2024Sep 30, 2024-$28.18M–
Q2 FY2024Jun 30, 2024-$69.07M–
Q1 FY2024Mar 31, 2024-$56.02M–
Q4 FY2023Dec 31, 2023-$54.18M–
Q3 FY2023Sep 30, 2023-$47.50M–
Q2 FY2023Jun 30, 2023-$51.83M–
Q1 FY2023Mar 31, 2023-$39.99M–
Q4 FY2022Dec 31, 2022-$41.87M–
Q3 FY2022Sep 30, 2022-$39.87M–
Q2 FY2022Jun 30, 2022-$27.90M–
Q1 FY2022Mar 31, 2022-$28.62M–
Q4 FY2021Dec 31, 2021-$30.92M–
Q3 FY2021Sep 30, 2021-$25.62M–
Q2 FY2021Jun 30, 2021-$28.84M–
Q1 FY2021Mar 31, 2021-$28.41M–
Q4 FY2020Dec 31, 2020-$23.22M–

More Geron figures

See a number that looks wrong?